Abstract
This is a report of microvascular changes seen on fluorescein angiography (FA) and optical coherence tomography angiography (OCTA) in a 47-year-old man with macular telangiectasia Type 1 (MacTel1) after a 7-year bevacizumab (Avastin; Genentech, South San Francisco, CA) treatment course. OCTA allowed for clear visualization of most telangiectasias and aneurysms in the deep capillary plexus, with only few microvascular dilatations in the superficial plexus. In addition, areas of capillary dropout in the superficial and deep vascular plexa located near telangiectasias were documented on OCTA. Serial FA demonstrated reduced number of aneurysms and telangiectasias at the 7-year mark compared to baseline.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 263-266 |
| Number of pages | 4 |
| Journal | Ophthalmic Surgery Lasers and Imaging Retina |
| Volume | 48 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2017 |
ASJC Scopus subject areas
- Surgery
- Ophthalmology
Fingerprint Dive into the research topics of 'Fluorescein angiography versus optical coherence tomography angiography in macular telangiectasia type i treated with bevacizumab therapy'. Together they form a unique fingerprint.
Cite this
Yannuzzi, N. A., Gregori, N., Roisman, L., Gupta, N., Goldhagen, B., & Goldhardt, R. (2017). Fluorescein angiography versus optical coherence tomography angiography in macular telangiectasia type i treated with bevacizumab therapy. Ophthalmic Surgery Lasers and Imaging Retina, 48(3), 263-266. https://doi.org/10.3928/23258160-20170301-12